

**FEDERAL EMERGENCY  
MANAGEMENT AGENCY****[FEMA-1069-DR]****Florida; Amendment to Notice of a  
Major Disaster Declaration****AGENCY:** Federal Emergency  
Management Agency (FEMA).**ACTION:** Notice.**SUMMARY:** This notice amends the notice of a major disaster for the State of Florida, (FEMA-1069-DR), dated October 4, 1995, and related determinations.**EFFECTIVE DATE:** October 12, 1995.**FOR FURTHER INFORMATION CONTACT:** Pauline C. Campbell, Response and Recovery Directorate, Federal Emergency Management Agency, Washington, DC 20472, (202) 646-3606.**SUPPLEMENTARY INFORMATION:** The notice of a major disaster for the State of Florida dated October 4, 1995, is hereby amended to include the following areas among those areas determined to have been adversely affected by the catastrophe declared a major disaster by the President in his declaration of October 4, 1995:

Franklin and Jackson Counties for Individual Assistance, Public Assistance, and Hazard Mitigation Assistance.

(Catalog of Federal Domestic Assistance No. 83.516, Disaster Assistance.)

Richard W. Krimm,

*Associate Director, Response and Recovery Directorate.*

[FR Doc. 95-25936 Filed 10-18-95; 8:45 am]

**BILLING CODE 6718-02-P****Notice of Adjustment of Disaster Grant  
Amounts****AGENCY:** Federal Emergency  
Management Agency (FEMA).**ACTION:** Notice.**SUMMARY:** The Federal Emergency Management Agency (FEMA) gives notice that the maximum amounts for Individual and Family Grants and grants to State and local governments and private nonprofit facilities are adjusted for disasters declared on or after October 1, 1995.**EFFECTIVE DATE:** October 1, 1995.**FOR FURTHER INFORMATION CONTACT:** Pauline C. Campbell, Response and Recovery Directorate, Federal Emergency Management Agency, Washington, DC 20472, (202) 646-3606.**SUPPLEMENTARY INFORMATION:** The Robert T. Stafford Disaster Relief and Emergency Assistance Act, Public Law 93-288, as amended, prescribes that

grants made under Section 411, Individual and Family Grant Program, and grants made under Section 422, Simplified Procedure, relating to the Public Assistance program, shall be adjusted annually to reflect changes in the Consumer Price Index for All Urban Consumers published by the Department of Labor.

Notice is hereby given that the maximum amount of any grant made to an individual or family for disaster-related serious needs and necessary expenses under Sec. 411 of the Act, with respect to any single disaster, is increased to \$12,900.00 for all disasters declared on or after October 1, 1995.

Notice is also hereby given that the amount of any grant made to the State, local government, or to the owner or operator of an eligible private nonprofit facility, under Sec. 422 of the Act, is increased to \$44,800.00 for all disasters declared on or after October 1, 1995.

The increase is based on a rise in the Consumer Price Index for All Urban Consumers of 2.6 percent for the prior 12-month period. The information was published by the Department of Labor during September 1995.

(Catalog of Federal Domestic Assistance No. 83.516, Disaster Assistance.)

James L. Witt,

*Director.*

[FR Doc. 95-25932 Filed 10-18-95; 8:45 am]

**BILLING CODE 6718-02-P****GENERAL ACCOUNTING OFFICE****Administrative Practice and Procedure,  
Reporting and Recording  
Requirements, Title 6: "Pay, Leave,  
and Allowances", "Policy and  
Procedures Manual for the Guidance of  
Federal Agencies"****AGENCY:** General Accounting Office.**ACTION:** Notice of document availability.**SUMMARY:** As part of its mandate to provide agencies useful guidance on accounting and internal control matters, GAO periodically updates and revises parts of its "Policy and Procedures Manual for Guidance of Federal Agencies." This notice indicates that proposed revisions to portions of Title 6, "Pay, Leave, and Allowances," of GAO's "Policy and Procedures Manual," are available from GAO for review and comment. These proposed revisions are intended to reflect changes in technology as well as changes in the law which have occurred since the last edition. Comments are being sought as part of the due process to revise portions of Title 6 and will be considered in the finalizing the revision.**DATES:** Comments must be received by December 18, 1995.**ADDRESSES:** Copies of the Title 6 draft are available by (1) pick-up at Document Distribution, U.S. General Accounting Office, Room 1100, 700 4th Street, NW. (corner of 4th and G Streets, NW.), Washington, DC., (2) mail from U.S. General Accounting Office, P.O. Box 6015, Gaithersburg, MD 20884-6015, or (3) phone at 202-512-6000 or FAX 301-258-4066. Comments should be addressed to the Accounting and Information Management Division, attention: Bruce Michelson, Room 6B12, U.S. General Accounting Office, 441 G Street, NW., Washington, DC 20548.**FOR FURTHER INFORMATION CONTACT:** Bruce Michelson, 202-512-9366.**SUPPLEMENTARY INFORMATION:** The revisions to Title 6 cover two main parts: time and attendance and the order of withholding precedence for deductions from federal employee pay. The changes to T & A reporting are a result of advancing technology and current initiatives to streamline and simplify administrative operations. This revision replaces chapter 3.

The changes on the order of withholding precedence are a result of regulations recently issued by the Office of Personnel Management in response to the requirements of the Hatch Act Reform Amendments of 1993 (Pub. L. 103-94), sec. 9, that was passed subsequent to the last revision of Title 6. This revision replaces section 5.3 in chapter 5.

Gene L. Dodaro,

*Assistant Comptroller General.*

[FR Doc. 95-25951 Filed 10-18-95; 8:45 am]

**BILLING CODE 1610-01-P****DEPARTMENT OF HEALTH AND  
HUMAN SERVICES****Office of the Secretary****Notice of Interest Rate on Overdue  
Debts**

Section 30.13 of the Department of Health and Human Services' claims collection regulations (45 CFR Part 30) provides that the Secretary shall charge an annual rate of interest as fixed by the Secretary of the Treasury after taking into consideration private consumer rates of interest prevailing on the date that HHS becomes entitled to recovery. The rate generally cannot be lower than the Department of Treasury's current value of funds rate or the applicable rate determined from the "Schedule of Certified Interest Rates with Range of Maturities." This rate may be revised

quarterly by the Secretary of the Treasury and shall be published quarterly by the Department of Health and Human Services in the Federal Register.

The Secretary of the Treasury has certified a rate of 13  $\frac{7}{8}$ % for the quarter ended September 30, 1995. This interest rate will remain in effect until such time as the Secretary of the Treasury notifies HHS of any change.

Dated: October 13, 1995.

George Strader,

*Deputy Assistant Secretary, Finance.*

[FR Doc. 95-25885 Filed 10-18-95; 8:45 am]

BILLING CODE 4150-04-M

## Food and Drug Administration

[Docket No. 95F-0331]

### BASF Aktiengesellschaft; Filing of Food Additive Petition

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing that BASF Aktiengesellschaft has filed a petition proposing that the food additive regulations be amended to provide for the safe use of polyaryletherketone resins (i.e., poly(oxy-1,4-phenylenecarbonyl-1,4-phenyleneoxy-1,4-phenylenecarbonyl-1,4-phenylenecarbonyl-1,4-phenylene) as a basic resin for use in food-contact materials.

**DATES:** Written comments on the petitioner's environmental assessment by November 20, 1995.

**ADDRESSES:** Submit written comments to the Dockets Management Branch (HFA-305), Food and Drug Administration, rm. 1-23, 12420 Parklawn Dr., Rockville, MD 20857.

**FOR FURTHER INFORMATION CONTACT:** Vir D. Anand, Center for Food Safety and Applied Nutrition (HFS-216), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-418-3081.

**SUPPLEMENTARY INFORMATION:** Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a food additive petition (FAP 5B4483) has been filed by BASF Aktiengesellschaft, c/o Keller and Heckman, 1001 G St. NW., suite 500 West, Washington, DC 20001. The petition proposes to amend the food additive regulations to provide for the safe use of polyaryletherketone resins (i.e., poly(oxy-1,4-phenylenecarbonyl-1,4-phenyleneoxy-1,4-phenylenecarbonyl-1,4-

phenylenecarbonyl-1,4-phenylene) as a basic resin for use in food-contact materials.

The potential environmental impact of this action is being reviewed. To encourage public participation consistent with regulations promulgated under the National Environmental Policy Act (40 CFR 1501.4(b)), the agency is placing the environmental assessment submitted with the petition that is the subject of this notice on display at the Dockets Management Branch (address above) for public review and comment. Interested persons may, on or before November 20, 1995, submit to the Dockets Management Branch (address above) written comments. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday. FDA will also place on public display any amendments to, or comments on, the petitioner's environmental assessment without further announcement in the Federal Register. If, based on its review, the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the Federal Register in accordance with 21 CFR 25.40(c).

Dated: October 3, 1995.

Alan M. Rulis,

*Acting Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.*

[FR Doc. 95-25765 Filed 10-18-95; 8:45 am]

BILLING CODE 4160-01-F

[Docket No. 95N-0334]

### Drug Export; Atrovent® (Ipratropium Bromide) Nasal Spray 0.03%, 10 Milliliter (mL) and 30 mL

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing that Boehringer Ingelheim Pharmaceuticals Inc., has filed an application requesting approval for the export of the human drug Atrovent® (ipratropium bromide) Nasal Spray 0.03%, 10 mL and 30 mL to Canada.

**ADDRESSES:** Relevant information on this application may be directed to the Dockets Management Branch (HFA-305), Food and Drug Administration, rm. 1-23, 12420 Parklawn Dr., Rockville, MD 20857, and to the contact person identified below. Any future inquiries concerning the export of human drugs under the Drug Export Amendments Act of 1986 should also be directed to the contact person.

**FOR FURTHER INFORMATION CONTACT:** James E. Hamilton, Center for Drug Evaluation and Research (HFD-310), Food and Drug Administration, 7520 Standish Pl., Rockville, MD 20855, 301-594-3150.

**SUPPLEMENTARY INFORMATION:** The drug export provisions in section 802 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 382) provide that FDA may approve applications for the export of drugs that are not currently approved in the United States. Section 802(b)(3)(B) of the act sets forth the requirements that must be met in an application for approval. Section 802(b)(3)(C) of the act requires that the agency review the application within 30 days of its filing to determine whether the requirements of section 802(b)(3)(B) have been satisfied. Section 802(b)(3)(A) of the act requires that the agency publish a notice in the Federal Register within 10 days of the filing of an application for export to facilitate public participation in its review of the application. To meet this requirement, the agency is providing notice that Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury Rd., Ridgefield, CT 06877, has filed an application requesting approval for the export of the human drug Atrovent® (ipratropium bromide) Nasal Spray 0.03%, 10 mL and 30 mL to Canada. This drug product is used for the symptomatic relief of rhinorrhea associated with allergic or non-allergic perennial rhinitis. The application was received and filed in the Center for Drug Evaluation and Research on September 28, 1995, which shall be considered the filing date for purposes of the act.

Interested persons may submit relevant information on the application to the Dockets Management Branch (address above) in two copies (except that individuals may submit single copies) and identified with the docket number found in brackets in the heading of this document. These submissions may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

The agency encourages any person who submits relevant information on the application to do so by October 30,